» Articles » PMID: 31892693

Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect

Overview
Journal Med Sci Monit
Date 2020 Jan 2
PMID 31892693
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Compound Kushen injection (CKI) is a traditional Chinese medicine preparation for clinical treatment of cancer pain or treatment of various types of solid tumors. The purpose of this study was to identify the main active compounds from CKI and to investigate its anti-cancer mechanisms via drug target biological network pharmacology construction and prediction. MATERIAL AND METHODS Constituents of CKI were retrieved from Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Disease targets were collected in the Human Gene (Gene Cards) and Human Mendelian Inheritance (OMIM) databases. "Ingredients-protein targets-pathway" networks were constructed using Cytoscape. STRING database platform to construct enrichment of protein-protein interactions (PPI), related diseases and pathways network. Gene Ontology (GO) biological functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of were performed to investigate by using Bioconductor tool for analysis. RESULTS The results indicated that 60 constituents of absorption, distribution, metabolism, and excretion (ADME) filtration resulted in 33 constituents exhibiting significant correlations with anti-cancer and CKI may target 113 proteins, including IL6, EGFR, CASP3, VEGFA, MYC, and ESR1. GO and KEGG enrichment analysis results show that 129 biological processes and 93 signal pathways associated with cancer. It mainly involves cancers such as prostate cancer, bladder cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, etc. Active ingredients might also induce apoptosis in cancer cells via the p53 and PI3K-Akt signaling pathway mechanism. CONCLUSIONS This study was based on pharmacological networks results for the prediction of the multi-constituent, multi-target, and multi-pathway mechanisms of CKI, which might be a promising potential therapeutic and prevention candidate for anti-cancer. However, based on computer data mining and analysis, this study still needs to be further verified by in vivo/in vitro experiments, and the safety of CKI needs to be evaluated.

Citing Articles

Efficacy and Safety of Compound Kushen Injection for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials with Trial Sequential Analysis.

Wu J, Ma X, Wang X, Zhu G, Wang H, Zhang Y Integr Cancer Ther. 2024; 23:15347354241258458.

PMID: 38853681 PMC: 11163932. DOI: 10.1177/15347354241258458.


Efficacy and safety of compound kushen injection for treating advanced colorectal cancer: A protocol for a systematic review and meta-analysis.

Wu J, Ma X, Wang X, Zhu G, Wang H, Li J Heliyon. 2024; 10(5):e26981.

PMID: 38463847 PMC: 10923683. DOI: 10.1016/j.heliyon.2024.e26981.


Analysis of Network Pharmacological Efficacy and Therapeutic Effectiveness in Animal Models for Functional Dyspepsia of .

Choi N, Jung D, Kim S, Park J, Choi W, Kim B Nutrients. 2023; 15(12).

PMID: 37375548 PMC: 10301275. DOI: 10.3390/nu15122644.


Identification of glycogen phosphorylase L as a potential target for lung cancer.

He X, Lyu W, Li X, Zhao H, Qi L, Lu J Med Oncol. 2023; 40(7):211.

PMID: 37347364 DOI: 10.1007/s12032-023-02069-8.


Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification.

Zhi G, Shao B, Zheng T, Mu J, Li J, Feng Y Front Pharmacol. 2023; 14:1082451.

PMID: 36762105 PMC: 9902723. DOI: 10.3389/fphar.2023.1082451.


References
1.
Xu X, Zhang W, Huang C, Li Y, Yu H, Wang Y . A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci. 2012; 13(6):6964-6982. PMC: 3397506. DOI: 10.3390/ijms13066964. View

2.
Yao Y, Rao C, Zheng G, Wang S . Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis. Oncol Rep. 2019; 42(1):131-141. PMC: 6549074. DOI: 10.3892/or.2019.7136. View

3.
Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K . Gene Therapy Leaves a Vicious Cycle. Front Oncol. 2019; 9:297. PMC: 6491712. DOI: 10.3389/fonc.2019.00297. View

4.
Rakibul Hasan M, Bari M, Alam S, Sah G . Concurrent Weekly versus Three Weekly Cisplatin with Radiotherapy in Locally Advanced Uterine Cervical Carcinoma. JNMA J Nepal Med Assoc. 2019; 56(213):842-847. PMC: 8959356. View

5.
Bartels S, Christgen M, Luft A, Persing S, Jodecke K, Lehmann U . Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. Mod Pathol. 2017; 31(1):56-61. DOI: 10.1038/modpathol.2017.95. View